Nu Skin Enterprises (NUS) Cash & Equivalents (2009 - 2026)

Nu Skin Enterprises has disclosed Cash & Equivalents across 18 years of filings, most recently posting $189.6 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 28.21% year-over-year to $189.6 million; the TTM figure through Jun 2026 stood at $189.6 million (down 28.21% YoY), while the FY2025 annual figure was $238.6 million, up 27.69% from the prior year.
• Cash & Equivalents came in at $189.6 million for Q2 2026 at Nu Skin Enterprises, down from $198.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $363.9 million in Q2 2022 to a low of $186.9 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $243.2 million, with a median of $234.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents slumped 35.27% in 2023 and gained 27.69% in 2025.
• Over 5 years, Cash & Equivalents stood at $264.7 million in 2022, then decreased by 3.27% to $256.1 million in 2023, then dropped by 27.02% to $186.9 million in 2024, then grew by 27.69% to $238.6 million in 2025, then decreased by 20.53% to $189.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $189.6 million in Q2 2026, $198.7 million in Q1 2026, and $238.6 million in Q4 2025.